View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 21, 2019

Bavarian Nordic reports Phase II bladder cancer trial data

Bavarian Nordic has reported results from the first stage of a Phase II clinical trial of CV301 in combination with atezolizumab to treat locally advanced or metastatic urothelial bladder cancer.

The combination therapy failed to achieve the efficacy threshold required to advance to stage II.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

CV301 is Bavarian Nordic’s cancer immunotherapy candidate, while atezolizumab is a checkpoint inhibitor being developed by Roche.

Stage I of the Phase II trial, which was sponsored by Bavarian Nordic, was performed in 27 patients across two cohorts. The first cohort assessed the combination as first-line treatment in urothelial bladder cancer patients who cannot receive cisplatin-containing chemotherapy.

The second cohort involved second-line therapy of participants who received prior cisplatin-based chemotherapy treatments.

Though clinical efficacy was observed in multiple participants, both cohorts did not meet the pre-defined clinical efficacy criteria to expand patient recruitment into stage II.

Bavarian Nordic president and CEO Paul Chaplin said: “While the results of this study are disappointing, they contribute to our overall understanding of our platform and provide important learnings to refine our approach to equip the body’s immune system with more weapons to fight cancer from within.”

The company is studying a combination of CV301 and checkpoint inhibitors in investigator-sponsored Phase II studies for colorectal and pancreatic cancers.

Bavarian Nordic also announced plans to focus on the development of its BN-Brachyury vaccine candidate, along with its new immuno-oncology strategy of intravenous and intratumoral administration.

BN-Brachyury is undergoing a Phase II trial for advanced chordoma. The company noted that the first stage of this trial demonstrated clinical activity, which in turn facilitated expanded enrolment.

Final results from the trial are expected to be available by late next year.

Bavarian Nordic is also planning for a separate trial of an intravenous formulation of BN-Brachyury.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena